Conjugates of an IL-2 moiety and a polymer

US9861705B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9861705-B2
Application numberUS-201113884901-A
CountryUS
Kind codeB2
Filing dateNov 11, 2011
Priority dateNov 12, 2010
Publication dateJan 9, 2018
Grant dateJan 9, 2018

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Conjugates of an interleukin-2 (“IL-2”) moiety and one or more nonpeptidic, water-soluble polymers are provided. Typically, the nonpeptidic, water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided, among other things, are compositions comprising conjugates, methods of making conjugates, methods of administering compositions to an individual, nucleic acid sequences, expression systems, host cells, and methods for preparing IL-moieties.

First claim

Opening claim text (preview).

What is claimed is: 1. A conjugate of an interleukin-2 (IL-2) moiety having the amino acid sequence of SEQ ID NO: 3, the conjugate comprising one to seven water-soluble polymers covalently attached via a releasable linkage to amino groups within the IL-2 moiety, wherein any given amino group within the IL-2 moiety has at most one water-soluble polymer covalently attached via the releasable linkage thereto, and further wherein: (i) each water-soluble polymer has a weight-average molecular weight in the range of from about 20,000 Daltons to about 85,000 Daltons; and (ii) at least one water-soluble polymer is releasably covalently attached at an amino group of a lysine within the IL-2 moiety. 2. The conjugate of claim 1 , wherein the water-soluble polymer is a branched water-soluble polymer. 3. The conjugate of claim 2 , wherein the branched water-soluble polymer is a branched poly(ethylene glycol). 4. The conjugate of claim 3 , wherein each branched poly(ethylene glycol) has a weight-average molecular weight of about 20,000 Daltons. 5. The conjugate of claim 4 , wherein each branched poly(ethylene glycol) comprises two poly(ethylene glycol) chains. 6. The conjugate of claim 1 , wherein the water-soluble polymer is a polymer selected from the group consisting of poly(alkylene oxide), poly(vinyl pyrrolidone), poly(vinyl alcohol), polyoxazoline, and poly(acryloylmorpholine). 7. The conjugate of claim 6 , wherein the water-soluble polymer is a poly(alkylene oxide). 8. The conjugate of claim 7 , wherein the poly(alkylene oxide) is a poly(ethylene glycol). 9. The conjugate of claim 8 , wherein the poly(ethylene glycol) is terminally capped with an end-capping moiety selected from the group consisting of hydroxy, alkoxy, substituted alkoxy, alkenoxy, substituted alkenoxy, alkynoxy, substituted alkynoxy, aryloxy and substituted aryloxy. 10. The conjugate of claim 1 , wherein one, two, three or four water-soluble polymers are attached to the residue of the IL-2 moiety. 11. The conjugate of claim 1 , wherein one, two or three water-soluble polymers are attached to the IL-2 moiety. 12. The conjugate of claim 1 , wherein one or two water-soluble polymers are attached to the IL-2 moiety. 13. The conjugate of claim 1 , wherein one water-soluble polymer is attached to the IL-2 moiety. 14. A composition comprising a plurality of conjugates according to claim 8 . 15. The composition of claim 14 , wherein the plurality of conjugates is a mixture of monoPEGylated, diPEGYlated and triPEGylated conjugates. 16. The composition of claim 14 , wherein the plurality of conjugates has four or more poly(ethylene glycol) polymers covalently attached to the IL-2 moiety. 17. A pharmaceutical composition comprising a conjugate of claim 1 and a pharmaceutically acceptable excipient. 18. A method comprising administering to an individual a pharmaceutical composition of claim 17 .

Assignees

Inventors

Classifications

  • Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title

  • for RNA viruses · CPC title

  • for HIV · CPC title

  • Immunostimulants · CPC title

  • Antineoplastic agents · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9861705B2 cover?
Conjugates of an interleukin-2 (“IL-2”) moiety and one or more nonpeptidic, water-soluble polymers are provided. Typically, the nonpeptidic, water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided, among other things, are compositions comprising conjugates, methods of making conjugates, methods of administering compositions to an individual, nucleic acid sequences,…
Who is the assignee on this patent?
Bossard Mary J, Ali Cherie F, Liu Xiaofeng, and 3 more
What technology area does this patent fall under?
Primary CPC classification A61K47/60. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Jan 09 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).